Stocks › ORMP
ORAMED PHARMACEUTICALS INC.
ORMP·Nasdaq·
United States·USD
United States·USD$4.38
-0.17 (-3.74%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
ORMP
ORAMED PHARMACEUTICALS INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ORMPS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ORMP by members of U.S. Congress · 4 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Brad KnottHouse · R · NC |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $15,001 - $50,000 |
Feb 25, 2025 | Jan 10, 2025 | Filing ↗ |
 Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $1,001 - $15,000 |
Jan 14, 2022 | Jan 14, 2022 | Filing ↗ |
| Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Sale $1,001 - $15,000 |
Nov 3, 2021 | Oct 1, 2021 | Filing ↗ |
| Andrew R. GarbarinoHouse · R · NY |
ORMPORAMED PHARMACEUTICALS INC. · Stock |
Purchase $1,001 - $15,000 |
May 24, 2021 | Apr 23, 2021 | Filing ↗ |
Whale Activity
Position changes in ORMP reported for 2026-06-30 by 7 tracked institutional filers
- Increased3
- New1
- Held0
- Decreased1
- Closed1
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Aquamarine Financial (Cayman) Ltd | 2.5M | $12.1M | — |
| BlackRock, Inc. | 1.6M | $7.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 229.9K | $1.1M | new |
| RENAISSANCE TECHNOLOGIES LLC | 183.8K | $884K | increased |
| CITADEL ADVISORS LLC | 41.6K | $200K | decreased |
| MILLENNIUM MANAGEMENT LLC | 21.9K | $105K | increased |
| Point72 Asset Management | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ORMP insiders, by quarter · Form 4
Recent Insider Transactions
258 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gabay AvrahamChief Financial Officer | Sale | −20.0K | $4.51 | $90K | Oct 1, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Sale | −30.0K | $4.51 | $135K | Oct 1, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Sale | −137.0K | $4.46 | $611K | Jul 1, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Sale | −73.4K | $4.51 | $331K | Jul 1, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Tax withholding | −44.8K | $3.31 | $148K | Mar 30, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Tax withholding | −435.1K | $3.31 | $1.4M | Mar 30, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Grant / award | +119.6K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +167.0K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Grant / award | +95.9K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Grant / award | +95.9K | $0.00 | $0 | Mar 17, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Gift | −100.0K | $0.00 | $0 | Mar 12, 2026 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Option exercise | +109.0K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Option exercise | +19.0K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| Hexter JoshuaCOO & CBO | Option exercise | +19.0K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| Gabay AvrahamChief Financial Officer | Option exercise | +19.0K | $0.00 | $0 | Jan 22, 2026 | Form 4 ↗ |
| Kidron MiriamChief Scientific Officer · Director | Gift | −86.2K | $0.00 | $0 | Jan 14, 2026 | Form 4 ↗ |
| Reznick YehudaDirector | Grant / award | +6,250 | — | — | Dec 31, 2025 | Form 4 ↗ |
| Reznick YehudaDirector | Grant / award | +30.0K | — | — | Dec 31, 2025 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +327.0K | $0.00 | $0 | Dec 31, 2025 | Form 4 ↗ |
| KIDRON NADAVPresident and CEO · Director | Grant / award | +232.6K | $0.00 | $0 | Dec 31, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ORMP · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF iShares Trust | 634.6K | $3.1M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 378.5K | $1.5M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 318.6K | $1.5M | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF iShares Trust | 115.0K | $553K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund SCHWAB CAPITAL TRUST | 83.6K | $340K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series Quantitative Master Series LLC | 63.6K | $306K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund Fidelity Salem Street Trust | 48.7K | $234K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund TIAA-CREF Funds | 46.4K | $189K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF Dimensional ETF Trust | 40.5K | $165K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio EQ Advisors Trust | 33.5K | $161K | 0.00% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ORMP's shares (CUSIP 68403P203), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Aquamarine Financial (Cayman) LtdSCHEDULE 13G/A · passive (13G) · 2.5M shares6.0%
Aug 14, 2026 · ↗ - Leonard Braden MichaelSCHEDULE 13G/A · passive (13G) · 1.0M shares2.5%
Jun 29, 2026 · ↗ - BML Investment Partners, L.P.SCHEDULE 13G/A · passive (13G) · 866.3K shares2.1%
Jun 29, 2026 · ↗ - Aquamarine Financial (Cayman) LtdSCHEDULE 13G · passive (13G) · 2.0M shares5.1%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming ORAMED PHARMACEUTICALS INC. as client
No lobbying filings found naming ORAMED PHARMACEUTICALS INC. as the client.
Government Contracts
Federal awards to ORAMED PHARMACEUTICALS INC. · USAspending
No federal contract awards found for ORAMED PHARMACEUTICALS INC..
U.S. Patents
Recent USPTO applications naming ORAMED PHARMACEUTICALS INC.
No USPTO patent applications found for ORAMED PHARMACEUTICALS INC..
Annual Financials
From ORMP's 10-K filings · XBRL
No annual XBRL figures on record for ORMP. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-12Reverse splitJan 23, 2013
Split dates and ratios from the price history · Close Prices from Tiingo.com
About ORAMED PHARMACEUTICALS INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE
SEC CIK0001176309 ↗
Former namesIntegrated Security Technologies, Inc., IGUANA VENTURES LTD